Please assess the completion status of the following clinical trial:

Trial Title: KD019 Versus Erlotinib in Subjects With Stage IIIB/IV Non Small Cell Lung Cancer With Progression After First- or Second-Line Chemotherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
For Eligibility subjects must have:~* failed one or two previous courses of therapy.~* have no active brain metastasis. Treated non-active brain metastasis are acceptable.~* cannot have received an Epidermal Growth Factor Receptors inhibitor (Tarceva \[erlotinib\] or Iressa \[gefitinib\]) in the past.~* has demonstrated progressive disease.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- KD019 (Type: EXPERIMENTAL): KD019 will be administered orally once daily at a dose of 300 mg. One dose reduction to 200 mg will be permitted.
- Erlotinib (Type: ACTIVE_COMPARATOR): Erlotinib will be administered orally once daily at a dose of 150 mg. One dose reduction to 100 mg daily will be permitted.

Based on this trial design, predict the completion outcome and termination type (if applicable).